[18F]DCFPyL PET/CT for Imaging of Prostate Cancer

Steven P. Rowe; Andreas Buck; Ralph A. Bundschuh; Constantin Lapa; Sebastian E. Serfling; Thorsten Derlin; Takahiro Higuchi; Michael A. Gorin; Martin G. Pomper; Rudolf A. Werner

doi:10.1055/a-1659-0010

Nuklearmedizin - NuclearMedicine, Table of Contents

CC BY 4.0 · Nuklearmedizin 2022; 61(03): 240-246
DOI: 10.1055/a-1659-0010

Review

[18F]DCFPyL PET/CT for Imaging of Prostate Cancer

[18F]DCFPyL PET/CT zur Prostatakarzinom-Bildgebung

Steven P. Rowe

¹The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, United States

²Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States

³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, United States

,

Andreas Buck

⁴Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)

,

Ralph A. Bundschuh

⁵Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany (Ringgold ID: RIN39062)

,

Constantin Lapa

⁶University of Augsburg, Augsburg, Germany (Ringgold ID: RIN26522)

,

Sebastian E. Serfling

⁴Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)

,

Thorsten Derlin

⁷Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany

,

Takahiro Higuchi

⁴Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)

⁸Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan

,

Michael A. Gorin

⁹Urology Associates and UPMC Western Maryland, Cumberland, United States

¹⁰Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, United States

,

Martin G. Pomper

¹The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, United States

²Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States

³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, United States

,

Rudolf A. Werner

⁴Nuclear Medicine, Würzburg University Medical Center Clinic for Nuclear Medicine, Würzburg, Germany (Ringgold ID: RIN526288)

› Author Affiliations

Abstract

Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, ⁶⁸Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of ¹⁸F-labeled agents. Among others, [¹⁸F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [¹⁸F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this ¹⁸F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [¹⁸F]DCFPyL in various clinical settings for men with PC.

Zusammenfassung

Die Positronen-Emissions-Tomografie (PET) mit PSMA (Prostata-spezifisches Membran-Antigen) gerichteten Liganden ist zunehmend in den Fokus der Bildgebung des Prostatakarzinoms (PC) bei Männern gerückt. In den letzten Jahren wurden in großem Umfang ⁶⁸Ga-markierte PSMA-Tracer verwendet, obwohl ein Trend zum verstärkten Einsatz von ¹⁸F-markierten Tracern zu beobachten ist. Unter anderem wurde [¹⁸F]DCFPyL (Piflufolastat F 18, PYLARIFY) in mehreren großen Studien wie OSPREY und CONDOR untersucht, die eine belastbare Evidenz für den klinischen Nutzen dieses Tracers hinsichtlich Staging, Restaging und Änderung des Managements zeigten. Neuere prospektive Untersuchungen haben [¹⁸F]DCFPyL PET/CT auch zur Beurteilung des Ansprechens eingesetzt, z. B. bei Patienten unter Abirateron oder Enzalutamid, was diesen ¹⁸F-markierten PSMA-Radiotracer zu einem attraktiven Biomarker für bildgestützte Strategien bei Männern mit PC macht. Nach der kürzlich erfolgten Zulassung durch die U.S. Food and Drug Administration (FDA) ist nicht nur in den USA, sondern langfristig auch in Europa mit einer breiteren Anwendung zu rechnen. Im vorliegenden Review geben wir einen Überblick über den aktuellen klinischen Nutzen von [¹⁸F]DCFPyL bei Männern mit PC in verschiedenen klinischen Situationen.

Schlüsselwörter

Prostatakarzinom - Theranostik - ¹⁸F-DCFPyL

Keywords

Prostate Cancer - Theranostics - ¹⁸F-DCFPyL

Full Text

References

References
1 Savir-Baruch B, Werner RA, Rowe SP. et al. PET Imaging for Prostate Cancer. Radiol Clin N Am 2021; 59: 801-811
2 Seifert R, Seitzer K, Herrmann K. et al. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy. Theranostics 2020; 10 (17) 7812-7820
3 Sartor O, de Bono J, Chi KN. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021; 385 (12) 1091-1103
4 Werner RA, Derlin T, Lapa C. et al. (18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics 2020; 10 (01) 1-16
5 Schmuck S, Mamach M, Wilke F. et al. Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging. Clin Nucl Med 2017; 42 (06) e286-e293
6 Morris MJ, Rowe SP, Gorin MA. et al. Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res 2021; 27 (13) 3674-3682
7 FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer. J Nucl Med 2021; 62 (08) 11N
8 Bouvet V, Wuest M, Jans HS. et al. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Res 2016; 6 (01) 40
9 Robu S, Schmidt A, Eiber M. et al. Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007. EJNMMI Res 2018; 8 (01) 30
10 Szabo Z, Mena E, Rowe SP. et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol 2015; 17 (04) 565-574
11 Jansen BHE, Cysouw MCF, Vis AN. et al. Repeatability of Quantitative (18)F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. J Nucl Med 2020; 61 (09) 1320-1325
12 Werner RA, Habacha B, Bundschuh L. et al. Test-Retest Reproducibility of Conventional Quantitative Parameters on PSMA-targeted 18F-DCFPyL PET/CT in Patients with Metastatic Prostate Cancer. J Nucl Med 2021; 62: 1317
13 Li X, Rowe SP, Leal JP. et al. Semiquantitative Parameters in PSMA-Targeted PET Imaging with (18)F-DCFPyL: Variability in Normal-Organ Uptake. J Nucl Med 2017; 58 (06) 942-6
14 Viner M, Mercier G, Hao F. et al. Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. Radiology 2013; 267 (02) 596-601
15 Werner RA, Bundschuh RA, Bundschuh L. et al. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Mol Imaging Biol 2020; 22 (01) 190-197
16 Sahakyan K, Li X, Lodge MA. et al. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Mol Imaging Biol 2020; 22 (01) 181-189
17 Rowe SP, Macura KJ, Mena E. et al. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol 2016; 18 (03) 411-419
18 Dietlein M, Kobe C, Kuhnert G. et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol 2015; 17 (04) 575-584
19 Giesel FL, Will L, Lawal I. et al. Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med 2018; 59 (07) 1076-1080
20 Wondergem M, van der Zant FM, Broos WA. et al. Matched-pair comparison of (18)F-DCFPyL PET/CT and (18)F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions. J Nucl Med 2021; 62 (10) 1422-1429
21 Rowe SP, Li X, Trock BJ. et al. Prospective Comparison of PET Imaging with PSMA-Targeted (18)F-DCFPyL Versus Na(18)F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. J Nucl Med 2020; 61 (02) 183-188
22 Fendler WP, Eiber M, Beheshti M. et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44 (06) 1014-1024
23 Wondergem M, van der Zant FM, Rafimanesh-Sadr L. et al. Effect of forced diuresis during 18F-DCFPyL PET/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder. Nucl Med Commun 2019; 40 (06) 652-656
24 Wondergem M, van der Zant FM, Knol RJJ. et al. (18)F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med 2017; 58 (11) 1797-1804
25 Sheikhbahaei S, Werner RA, Solnes LB. et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Semin Nucl Med 2019; 49 (04) 255-270
26 Salas Fragomeni RA, Pienta KJ, Pomper MG. et al. Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. Clin Nucl Med 2018; 43 (11) e419-e421
27 Werner RA, Sheikhbahaei S, Jones KM. et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Ann Nucl Med 2017; 31 (09) 696-702
28 Werner RA, Bundschuh RA, Bundschuh L. et al. Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med 2019; 60 (05) 577-584
29 Eiber M, Herrmann K, Calais J. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med 2018; 59 (03) 469-478
30 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019; 5 (06) 856-863
31 Spak DA, Plaxco JS, Santiago L. et al. BI-RADS((R)) fifth edition: A summary of changes. Diagn Interv Imaging 2017; 98 (03) 179-190
32 Rowe SP, Pienta KJ, Pomper MG. et al. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. Eur Urol 2018; 73 (04) 485-487
33 Werner RA, Bundschuh RA, Bundschuh L. et al. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on (18)F-DCFPyL PET/CT Imaging. J Nucl Med 2018; 59 (12) 1857-64
34 Ashrafinia M, Sadaghiani MS, Dalaie P. et al. Characterization of Segmented 18F-DCFPyL PET/CT Lesions in the Context of PSMA-RADS Structured Reporting. J Nucl Med 2019; 60: 1565
35 Ceci F, Oprea-Lager DE, Emmett L. et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 2021; 48 (05) 1626-1638
36 Wondergem M, van der Zant FM, Roeleveld TA. et al. 18F-DCFPyL PET/CT in primary staging of prostate cancer. European J Hybrid Imaging 2018; 2: 26
37 Gorin MA, Rowe SP, Patel HD. et al. Prostate Specific Membrane Antigen Targeted (18)F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 2018; 199 (01) 126-132
38 Pienta KJ, Gorin MA, Rowe SP. et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol 2021; 206 (01) 52-61
39 Budaus L, Leyh-Bannurah SR, Salomon G. et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016; 69 (03) 393-396
40 Meijer D, Jansen BHE, Wondergem M. et al. Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS One 2020; 15 (10) e0239414
41 Dietlein F, Kobe C, Neubauer S. et al. PSA-Stratified Performance of (18)F- and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 2017; 58 (06) 947-952
42 Song H, Harrison C, Duan H. et al. Prospective Evaluation of (18)F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. J Nucl Med 2020; 61 (04) 546-551
43 Rowe SP, Campbell SP, Mana-Ay M. et al. Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. J Nucl Med 2020; 61 (01) 58-61
44 Lindenberg L, Mena E, Turkbey B. et al. Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of (18)F-DCFPyL PET/CT with Comparison to Multiparametric MRI. Radiology 2020; 296 (03) 564-572
45 True LD, Chen DL. How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?. Clin Cancer Res 2021; 27 (13) 3512-4
46 Phillips R, Shi WY, Deek M. et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020; 6 (05) 650-659
47 Pan KH, Wang JF, Wang CY. et al. Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis. Front Oncol 2020; 10: 597422
48 Zukotynski KA, Emmenegger U, Hotte S. et al. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted (18)F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. J Nucl Med 2021; 62 (10) 1430-1437
49 Markowski MC, Velho PI, Eisenberger MA. et al. Detection of Early Progression with (18)F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. J Nucl Med 2021; 62 (09) 1270-1273
50 Lovrec P, Bradshaw T, Kyriakopoulos C. et al. PSMA-based 18F-DCFPyL PET/MRI for Prediction of Progression and Assessment of Response to Neo-Adjuvant Chemohormonal Therapy in Men with High-Risk Primary Prostate Cancer. J Nucl Med 2021; 2021 (62) 1356
51 Leung K, Ashrafinia S, Sadaghiani MS. et al. A fully automated deep-learning based method for lesion segmentation in 18F-DCFPyL PSMA PET images of patients with prostate cancer. J Nucl Med 2019; 60: 399
52 Salas Fragomeni RA, Amir T, Sheikhbahaei S. et al. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. J Nucl Med 2018; 59 (06) 871-877
53 Rowe SP, Gorin MA, Hammers HJ. et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med 2015; 29 (10) 877-882
54 Meyer AR, Carducci MA, Denmeade SR. et al. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted (18)F-DCFPyL PET/CT. Ann Nucl Med 2019; 33 (08) 617-623
55 Roy J, Warner BM, Basuli F. et al. Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study. EJNMMI Res 2021; 11 (01) 66
56 Widjaja L, Werner RA, Ross TL. et al. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy. Cancers (Basel) 2021; 13 (12) 2938
57 Grubmuller B, Senn D, Kramer G. et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46 (05) 1063-1072